A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT02078609 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

AML and High Risk MDS

Interventions

DRUG: LGH447
DRUG: LGH447 + midostaurin

Sponsor

Novartis Pharmaceuticals